Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis
The role of co-agonists of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) in chronic kidney disease (CKD) remains unclear. Herein we found that GLP-1R and GCGR expression levels were lower in the kidneys of mice with CKD compared to healthy mice and were correlated with disea...
Saved in:
Main Authors: | Qian Zhao (Author), Jiale Dong (Author), Han Liu (Author), Hui Chen (Author), Huan Yu (Author), Shuyin Ye (Author), Shuangjin Yu (Author), Yu Li (Author), Longhui Qiu (Author), Nazi Song (Author), Hongjiao Xu (Author), Qi Liu (Author), Zhiteng Luo (Author), Yuyi Li (Author), Rui Wang (Author), Guodong Chen (Author), Xianxing Jiang (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis
by: Nazi Song, et al.
Published: (2022) -
Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
by: Magdalena Mazurek, et al.
Published: (2023) -
Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
by: Dan Xu, et al.
Published: (2022) -
Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
by: W. Timothy Garvey, et al.
Published: (2024) -
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
by: Patrick J. Knerr, et al.
Published: (2022)